See more : RIT Capital Partners plc (RCP.L) Income Statement Analysis – Financial Results
Complete financial analysis of Capricor Therapeutics, Inc. (CAPR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Capricor Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- First Foods Group, Inc. (FIFG) Income Statement Analysis – Financial Results
- INSU Acquisition Corp. III (IIII) Income Statement Analysis – Financial Results
- xReality Group Limited (XRG.AX) Income Statement Analysis – Financial Results
- TH Plantations Berhad (5112.KL) Income Statement Analysis – Financial Results
- Xinjiang Torch Gas Co., Ltd (603080.SS) Income Statement Analysis – Financial Results
Capricor Therapeutics, Inc. (CAPR)
About Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.18M | 2.55M | 244.90K | 310.25K | 1.01M | 1.67M | 1.37M | 3.19M | 3.78M | 4.79M | 503.23K | 195.50K | 1.35M | 0.00 | 0.00 | 0.00 | 101.40K | 0.00 | 0.00 | 0.00 | 2.18K | 11.48K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.07M | 694.87K | 245.70K | 8.46M | 5.14M | 12.07M | 10.77M | 16.04M | 13.76M | 7.79M | 5.20M | 2.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 24.11M | 1.85M | -799.00 | -8.15M | -4.14M | -10.40M | -9.40M | -12.85M | -9.98M | -3.00M | -4.69M | -2.44M | 1.35M | 0.00 | 0.00 | 0.00 | 101.40K | 0.00 | 0.00 | 0.00 | 2.18K | 11.48K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 95.75% | 72.74% | -0.33% | -2,625.87% | -411.61% | -621.98% | -687.46% | -402.87% | -264.33% | -62.69% | -932.76% | -1,247.43% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 36.45M | 21.82M | 13.57M | 8.46M | 5.14M | 12.07M | 10.77M | 16.04M | 13.76M | 7.79M | 5.20M | 1.02M | 4.14M | 4.08M | 4.47M | 9.48M | 5.12M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 12.37M | 10.43M | 7.61M | 5.54M | 3.60M | 4.93M | 4.76M | 4.93M | 4.37M | 3.02M | 2.21M | 1.61M | 2.12M | 2.21M | 3.42M | 3.92M | 4.48M | 60.40K | 18.86K | 18.98K | 18.34K | 29.26K | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.43K | 0.00 |
| SG&A | 12.37M | 10.43M | 7.61M | 5.54M | 3.60M | 4.93M | 4.76M | 4.93M | 4.37M | 3.02M | 2.21M | 1.61M | 2.12M | 2.21M | 3.42M | 3.92M | 4.48M | 60.40K | 18.86K | 18.98K | 18.34K | 29.26K | 22.22K | 10.43K | 0.00 |
| Other Expenses | 0.00 | 190.58K | 548.21K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 545.88K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 83.00 | 26.09K | 200.00 |
| Operating Expenses | 48.19M | 32.25M | 21.18M | 14.00M | 8.74M | 17.00M | 14.23M | 20.17M | 16.39M | 10.80M | 7.41M | 2.64M | 6.25M | 6.29M | 7.88M | 13.40M | 9.60M | 60.40K | 18.86K | 18.98K | 18.34K | 29.26K | 22.30K | 36.52K | 200.00 |
| Cost & Expenses | 49.26M | 32.25M | 21.18M | 14.00M | 8.74M | 17.00M | 14.23M | 20.17M | 16.39M | 10.80M | 7.41M | 2.64M | 6.25M | 6.29M | 7.88M | 13.40M | 9.60M | 60.40K | 18.86K | 18.98K | 18.34K | 29.26K | 22.30K | 36.52K | 200.00 |
| Interest Income | 1.73M | 0.00 | 57.46K | 32.94K | 94.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.23K | 6.01K | 20.38K | 47.19K | 332.72K | 287.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 398.81K | 344.67K | 248.63K | 200.51K | 58.13K | 0.00 | 0.00 | 0.00 | 0.00 | 137.00 | 1.09M | 950.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.07M | 694.87K | 245.70K | 143.89K | 171.96K | 157.65K | 144.17K | 134.64K | 110.87K | 41.90K | 26.92K | 6.26K | 7.51K | 12.93K | 159.59K | 113.29K | 26.98K | 0.00 | 0.00 | -900.00 | 0.00 | -2.19K | 83.00 | 200.00 | 200.00 |
| EBITDA | -23.01M | -29.16M | -20.69M | -13.55M | -7.56M | -15.17M | -12.72M | -18.33M | -12.50M | -5.97M | -6.88M | -1.89M | -4.88M | -6.02M | -7.71M | -13.02M | -9.50M | -2.50M | -18.86K | -19.88K | -16.16K | -19.97K | -22.22K | -36.32K | 200.00 |
| EBITDA Ratio | -91.39% | -1,184.21% | -8,700.01% | -4,423.18% | -778.68% | -917.04% | -940.79% | -532.16% | -334.00% | -124.85% | -1,366.36% | -1,244.33% | -361.76% | 0.00% | 0.00% | 0.00% | -9,342.68% | 0.00% | 0.00% | 0.00% | -739.79% | -173.90% | 0.00% | 0.00% | 0.00% |
| Operating Income | -24.08M | -29.70M | -20.94M | -13.69M | -7.73M | -15.33M | -12.86M | -16.98M | -12.61M | -6.02M | -6.90M | -2.44M | -4.90M | -6.29M | -7.88M | -13.40M | -9.50M | -60.40K | -18.86K | -18.98K | -16.16K | -17.78K | -22.30K | -36.52K | -200.00 |
| Operating Income Ratio | -95.63% | -1,165.10% | -8,549.86% | -4,412.56% | -769.52% | -917.04% | -940.79% | -532.16% | -334.00% | -125.72% | -1,371.71% | -1,248.15% | -361.70% | 0.00% | 0.00% | 0.00% | -9,369.29% | 0.00% | 0.00% | 0.00% | -739.79% | -154.82% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.79M | 677.85K | 915.92K | 32.94K | 92.07K | 135.99K | 15.29M | -1.83M | -245.51K | -198.61K | -1.99M | 207.00K | 14.39K | 262.06K | 11.41K | 268.39K | -802.34K | -950.00 | 0.00 | 900.00 | 16.16K | 2.19K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -22.29M | -29.02M | -20.02M | -13.66M | -7.64M | -15.19M | 2.43M | -18.81M | -12.86M | -6.22M | -8.89M | -1.89M | -4.88B | -6.03B | -7.87B | -13.13B | -10.30M | -61.35K | 0.00 | -18.08K | 0.00 | -15.59K | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -88.52% | -1,138.50% | -8,175.86% | -4,401.94% | -760.36% | -908.91% | 177.84% | -589.53% | -340.50% | -129.87% | -1,766.96% | -968.31% | -360,633.89% | 0.00% | 0.00% | 0.00% | -10,160.55% | 0.00% | 0.00% | 0.00% | 0.00% | -135.73% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -677.85 | -613.41K | -176.83K | -264.03K | 135.99K | 254.63K | 218.95K | 137.76K | 200.51K | 58.13K | 0.00 | -14.39K | -262.06K | -11.41K | -268.39K | 1.09M | 0.00 | 18.86K | 0.00 | 16.16K | 0.00 | 0.00 | 0.00 | 200.00 |
| Net Income | -22.29M | -29.02M | -19.41M | -13.48M | -7.38M | -15.19M | 2.43M | -18.81M | -12.86M | -6.22M | -8.89M | -1.89M | -4.88M | -6.03M | -7.87M | -13.13M | -10.30M | -61.35K | -18.86K | -18.08K | -16.16K | -15.59K | -22.30K | -36.52K | -200.00 |
| Net Income Ratio | -88.52% | -1,138.48% | -7,925.38% | -4,344.95% | -734.09% | -908.91% | 177.84% | -589.53% | -340.50% | -129.87% | -1,766.96% | -968.31% | -360.63% | 0.00% | 0.00% | 0.00% | -10,160.55% | 0.00% | 0.00% | 0.00% | -739.79% | -135.73% | 0.00% | 0.00% | 0.00% |
| EPS | -0.83 | -1.18 | -0.84 | -0.87 | -1.99 | -5.17 | 1.00 | -10.14 | -8.09 | -5.31 | -8.47 | -1.90 | -65.43 | -93.75 | -154.56 | -272.15 | -304.06 | -2.22 | -12.49 | -11.97 | -10.70 | -10.32 | -14.77 | -26.56 | -0.20 |
| EPS Diluted | -0.83 | -1.18 | -0.84 | -0.87 | -1.99 | -5.17 | 0.90 | -10.14 | -8.09 | -5.31 | -8.47 | -1.90 | -65.43 | -93.75 | -154.56 | -272.15 | -304.06 | -2.22 | -12.49 | -11.97 | -10.70 | -10.32 | -14.77 | -26.56 | -0.20 |
| Weighted Avg Shares Out | 26.78M | 24.55M | 23.09M | 15.57M | 3.71M | 2.94M | 2.32M | 1.86M | 1.59M | 1.17M | 1.05M | 994.52K | 74.66K | 64.34K | 50.93K | 48.25K | 33.88K | 27.59K | 1.51K | 1.51K | 1.51K | 1.51K | 1.51K | 1.38K | 1.00K |
| Weighted Avg Shares Out (Dil) | 26.78M | 24.55M | 23.09M | 15.57M | 3.71M | 2.94M | 2.68M | 1.86M | 1.59M | 1.17M | 1.05M | 994.53K | 74.66K | 64.34K | 50.93K | 48.25K | 33.88K | 27.59K | 1.51K | 1.51K | 1.51K | 1.51K | 1.51K | 1.38K | 1.00K |
Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission
Capricor Therapeutics initiated its rolling BLA submission for Deramiocel to treat Duchenne Muscular Dystrophy Cardiomyopathy, with completion expected before the end of 2024. The company presented promising 3-year data from the HOPE-2 OLE study, showing significant improvements in cardiac and...
Capricor Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is scheduled to present at the following upcoming...
Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants A.J. Bergmann - Chief Financial Officer Linda Marbán - Chief Executive Officer Conference Call Participants Ted Tenthoff - Piper Sandler Leland Gershell...
Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue Estimates
Capricor Therapeutics (CAPR) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.25 per share a year ago.
Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the third quarter ended September 30, 2024...
Here's Why Momentum in Capricor (CAPR) Should Keep going
Capricor (CAPR) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Is Capricor Therapeutics (CAPR) Outperforming Other Medical Stocks This Year?
Here is how Capricor Therapeutics (CAPR) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year.
Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline
Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced today the closing of its previously announced underwritten public offering of 5,073,800...
Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock
SAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the pricing of its underwritten offering of 4,412,000 shares of common...
Source: https://incomestatements.info
Category: Stock Reports